Full 3D Eye Modeling in the Diagnosis and Treatment of Lens Diseases With Eye Structures Disorders
NCT ID: NCT07321769
Last Updated: 2026-01-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1200 participants
OBSERVATIONAL
2020-01-01
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Predictive Performance of a Generative Model for Corneal Tomography After ICL Implantation
NCT07146737
Study on the Application of Intraoperative Optical Coherence Tomography Technique in the Diagnosis and Treatment of Lens Diseases
NCT06687356
Evaluating Presbyopia-Correcting IOLs in Complex Cataract Cases With Anterior Segment Abnormalities
NCT07321756
IOL-capsular Complex After Different Intraocular Lenses Implantation in Patients With High Myopia
NCT05255796
Dysfunctional Lens Index Serves as a Novel Surgery Decision Maker for Age-related Cataracts
NCT03340389
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study employs a retrospective research design. Using multimodal imaging systems-including anterior segment swept-source optical coherence tomography (SS-OCT), CT, B-scan ultrasound, and ultrasound biomicroscopy (UBM)-we aim to explore methods for full-eye three-dimensional reconstruction. The goal is to construct a comprehensive 3D ocular model that includes the cornea, anterior chamber, iris, angle, lens, vitreous cavity, retina, and related fundus structures.
This model will be used to comprehensively analyze morphological and spatial alterations in lens diseases associated with ocular spatial abnormalities, providing an objective quantitative description. Furthermore, the study will validate the effectiveness of this full 3D ocular model in clinical diagnosis, surgical planning, and prognosis assessment for this broad category of conditions. Ultimately, it seeks to establish objective, quantitative reference standards for the precise diagnosis and treatment of lens diseases complicated by ocular spatial structural disorders.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Toward 3D Modeling for Lens Disorders Associated with Congenital Anomalies
Part I: Exploration and research on full three-dimensional modeling in the diagnosis and treatment of lens diseases with congenital developmental anomaliesa
No interventions assigned to this group
Toward 3D Modeling for Reconstructive Management of Ocular Trauma
Part II: Exploration and research on full three-dimensional modeling for the reconstruction and treatment of ocular trauma
No interventions assigned to this group
Toward 3D Modeling for IOL Spatial Positioning
Part III: Exploration and research on full three-dimensional modeling for the spatial positioning of pseudophakic eyes
No interventions assigned to this group
Toward 3D Modeling for Cataracts with Iris/Pupillary Abnormalities
Part IV: Exploration and research on full three-dimensional modeling for cataract patients with iris or pupillary abnormalities
No interventions assigned to this group
Toward 3D Modeling for Cataracts with Posterior Segment Diseases
Part V: Exploration and research on full three-dimensional modeling for the management and treatment of cataract patients with posterior segment diseases
No interventions assigned to this group
Normal Control Group
Exploration and research on full three-dimensional modeling for individuals with no significant structural ocular diseases served as the normal control group.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1\) Diagnosed with lens disorders such as lens subluxation or deformity via imaging (slit-lamp, UBM) or clinical examination, combined with conditions such as megalocornea, microcornea, nanophthalmos, keratoconus, or iris coloboma; 2) Presence of imageable ocular structures; 3) Able to cooperate with and complete relevant examinations including B-scan ultrasound, UBM, and anterior segment SS-OCT.
* Part II: Toward 3D Modeling for Reconstructive Management of Ocular Trauma 1) Diagnosed with previous or stabilized corneal trauma, traumatic cataract, or iris injury, with or without associated vitreous traction or retinal damage; 2) Patients with open globe injuries that have been managed, with closed wounds and no endophthalmitis; 3) Able to cooperate with and complete relevant examinations including B-scan ultrasound, UBM, anterior segment SS-OCT, and CT.
* Part III:Toward 3D Modeling for IOL Spatial Positioning 1) Patients who have undergone cataract extraction with intraocular lens (IOL) implantation (in-the-bag or scleral-fixated); 2) Stable IOL position post-implantation with clear documentation of IOL parameters; 3) Able to cooperate with and complete relevant examinations including B-scan ultrasound, UBM, and anterior segment SS-OCT.
* Part IV: Toward 3D Modeling for Cataracts with Iris/Pupillary Abnormalities
1. Patients with iris morphological or positional abnormalities due to previous uveitis, trauma, or developmental anomalies (e.g., iris atrophy, synechiae, iridodialysis, polycoria, pupillary membrane remnants); 2) Able to cooperate with and complete relevant examinations including B-scan ultrasound, UBM, and anterior segment SS-OCT.
* Part V: Toward 3D Modeling for Cataracts with Posterior Segment Diseases
1\) Patients with various posterior segment vitreoretinal diseases (e.g., vitreous traction or proliferation, macular hole, epiretinal membrane), with or without anterior segment spatial structural abnormalities; 2) Able to cooperate with and complete relevant examinations including B-scan ultrasound, UBM, and anterior/posterior segment SS-OCT.
* Part VI: Normal Control Group
1. No significant structural ocular diseases; 2) Healthy fellow eyes of unilateral ocular trauma patients from Part II, with no notable anterior or posterior segment abnormalities; 3) Able to cooperate with and complete relevant examinations including B-scan ultrasound, UBM, anterior/posterior segment SS-OCT, and CT.
Exclusion Criteria
1\) Concurrent open globe injury or severe ocular deformity; 2) Excessive corneal opacity or severe edema resulting in inadequate image quality; 3) Severe dry eye or tear film abnormalities affecting imaging;4) Severe ocular structural deformity preventing effective 3D model reconstruction; 5) Severe systemic disease precluding tolerance of the examination; 6) Contraindications to B-scan ultrasound or UBM, conditions impairing imaging, or allergy to coupling gel.
* Part II: Toward 3D Modeling for Reconstructive Management of Ocular Trauma
1\) Unmanaged open globe injury or severe ocular deformity; 2) Severe systemic disease precluding tolerance of the examination; 3) Contraindications to CT imaging (e.g., metallic implants in the head/face region, pregnancy, lactation) or history of contrast medium allergy/adverse reactions.
* Part III: Toward 3D Modeling for IOL Spatial Positioning
1\) Unclear IOL position or documented implantation failure; 2) Corneal opacity or severe pupillary abnormality affecting imaging; 3) IOL instability due to intra- or postoperative complications preventing imaging;4) Open globe injury or severe ocular deformity; 5) Severe systemic disease precluding tolerance of the examination; 6) Contraindications to B-scan ultrasound or UBM, conditions impairing imaging, or allergy to coupling gel.
* Part IV: Toward 3D Modeling for Cataracts with Iris/Pupillary Abnormalities
1\) Corneal opacity or hyphema preventing imaging; 2) Severe global ocular deformity precluding imaging; 3) Severe systemic disease precluding tolerance of examination or follow-up; 4) Contraindications to B-scan ultrasound or UBM, conditions impairing imaging, or allergy to coupling gel.
* Part V: Toward 3D Modeling for Cataracts with Posterior Segment Diseases
1\) Severe structural deformity of both anterior and posterior segments preventing effective 3D model reconstruction; 2) Severe systemic disease precluding tolerance of examination or follow-up; 3) Contraindications to B-scan ultrasound or UBM, conditions impairing imaging, or allergy to coupling gel.
* Part VI: Normal Control Group 1) History of severe ocular trauma or ocular surgery; 2) Conditions affecting imaging quality, including corneal opacity, severe dry eye, tear film abnormalities, anterior segment disease, or significant retinal pathology; 3) Severe systemic disease precluding tolerance of the examination; 4) Contraindications to CT imaging (e.g., metallic implants in the head/face region, pregnancy, lactation) or history of contrast medium allergy/adverse reactions.
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Wen Xu, Phd
Role: PRINCIPAL_INVESTIGATOR
Second Affiliated Hospital, School of Medicine, Zhejiang University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Second Affiliated Hospital, Zhejiang University School of Medicine,
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025-1229
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.